Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma

被引:0
|
作者
Tan, Carlyn Rose [1 ]
Maclachlan, Kylee [2 ]
Nemirovsky, David [3 ]
Derkach, Andriy [1 ]
Hultcrantz, Malin [2 ]
Hassoun, Hani [2 ]
Mailankody, Sham [2 ]
Shah, Urvi [2 ]
Patel, Dhwani [1 ]
Shekarkhand, Tala [1 ]
Rueda, Colin [1 ]
Lahoud, Oscar [1 ]
Shah, Gunjan [1 ]
Scordo, Michael [1 ]
Chung, David [4 ]
Landau, Heather [4 ]
Giralt, Sergio [1 ]
Usmani, Saad [1 ]
Lesokhin, Alexander [1 ]
Korde, Neha [2 ]
机构
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA
[3] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY USA
[4] Mem Sloan Kettering Canc Ctr, Bone Marrow Transplant & Cellular Therapy, New York, NY USA
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P166
引用
收藏
页码:S127 / S127
页数:1
相关论文
共 50 条
  • [41] Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma
    Mizuno, Shinichi
    Kitayama, Chigusa
    Mashiko, Shigeto
    Sanada, Satoru
    CEN CASE REPORTS, 2022, 11 (02) : 265 - 268
  • [42] Renal recovery following daratumumab, lenalidomide, and dexamethasone therapy in a patient with newly diagnosed dialysis-dependent multiple myeloma
    Shinichi Mizuno
    Chigusa Kitayama
    Shigeto Mashiko
    Satoru Sanada
    CEN Case Reports, 2022, 11 : 265 - 268
  • [43] EFFICACY BY CYTOGENETIC RISK STATUS FOR DARATUMUMAB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE OR BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
    San-Miguel, J.
    Weisel, K.
    Cook, G.
    Leiba, M.
    Suzuki, K.
    Kumar, S.
    Cavo, M.
    Avet-Loiseau, H.
    Quach, H.
    Hungria, V.
    Lentzsch, S.
    Hajek, R.
    Sonneveld, P.
    Wu, K.
    Qin, X.
    Chiu, C.
    Soong, D.
    Qi, M.
    Schecter, J.
    Dimopoulos, M. A.
    HAEMATOLOGICA, 2017, 102 : 1 - 2
  • [44] Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
    Palumbo, Antonio
    Chanan-Khan, Asher
    Weisel, Katja
    Nooka, Ajay K.
    Masszi, Tamas
    Beksac, Meral
    Spicka, Ivan
    Hungria, Vania
    Munder, Markus
    Mateos, Maria V.
    Mark, Tomer M.
    Qi, Ming
    Schecter, Jordan
    Amin, Himal
    Qin, Xiang
    Deraedt, William
    Ahmadi, Tahamtan
    Spencer, Andrew
    Sonneveld, Pieter
    NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (08): : 754 - 766
  • [45] A plain language summary of the final analysis of the GRIFFIN study of daratumumab plus lenalidomide, bortezomib, and dexamethasone for people with newly diagnosed multiple myeloma
    Voorhees, Peter M.
    Sborov, Douglas W.
    Laubach, Jacob
    Kaufman, Jonathan L.
    Reeves, Brandi
    Rodriguez, Cesar
    Silbermann, Rebecca
    Costa, Luciano J.
    Anderson, Larry D.
    Nathwani, Nitya
    Shah, Nina
    Bumma, Naresh
    Efebera, Yvonne A.
    Holstein, Sarah A.
    Costello, Caitlin
    Jakubowiak, Andrzej
    Wildes, Tanya M.
    Orlowski, Robert Z.
    Shain, Kenneth H.
    Cowan, Andrew J.
    Dinner, Shira
    Gries, Katharine S.
    Pei, Huiling
    Cortoos, Annelore
    Patel, Sharmila
    Lin, Thomas S.
    Usmani, Saad Z.
    Richardson, Paul G.
    FUTURE ONCOLOGY, 2025, 21 (01) : 25 - 49
  • [46] Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China-Compared with bortezomib/lenalidomide/dexamethasone
    Huo, Zhongjun
    Chen, Fang
    Liu, Ping
    Luo, Zimian
    CANCER MEDICINE, 2023, 12 (03): : 2937 - 2944
  • [47] Treatment With Carfilzomib-Lenalidomide-Dexamethasone With Lenalidomide Extension in Patients With Smoldering or Newly Diagnosed Multiple Myeloma
    Korde, Neha
    Roschewski, Mark
    Zingone, Adriana
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Mailankody, Sham
    Wu, Peter
    Morrison, Candis
    Costello, Rene
    Zhang, Yong
    Burton, Debra
    Mulquin, Marcia
    Zuchlinski, Diamond
    Lamping, Liz
    Carpenter, Ashley
    Wall, Yvonne
    Carter, George
    Cunningham, Schuyler C.
    Gounden, Verena
    Sissung, Tristan M.
    Peer, Cody
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Kong, Katherine A.
    Weng, Li
    Faham, Malek
    Lindenberg, Liza
    Kurdziel, Karen
    Choyke, Peter
    Steinberg, Seth M.
    Figg, William
    Landgren, Ola
    JAMA ONCOLOGY, 2015, 1 (06) : 746 - 754
  • [48] Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX
    Dimopoulos, Meletios A.
    San-Miguel, Jesus
    Belch, Andrew
    White, Darrell
    Benboubker, Lotfi
    Cook, Gordon
    Leiba, Merav
    Morton, James
    Ho, P. Joy
    Kim, Kihyun
    Takezako, Naoki
    Moreau, Philippe
    Kaufman, Jonathan L.
    Sutherland, Heather J.
    Lalancette, Marc
    Magen, Hila
    Iida, Shinsuke
    Kim, Jin Seok
    Prince, H. Miles
    Cochrane, Tara
    Oriol, Albert
    Bahlis, Nizar J.
    Chari, Ajai
    O'Rourke, Lisa
    Wu, Kaida
    Schecter, Jordan M.
    Casneuf, Tineke
    Chiu, Christopher
    Soong, David
    Sasser, A. Kate
    Khokhar, Nushmia Z.
    Avet-Loiseau, Herve
    Usmani, Saad Z.
    HAEMATOLOGICA, 2018, 103 (12) : 2088 - 2096
  • [49] Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update
    Basu, Supratik
    Kumar, Shaji K.
    Moreau, Philippe
    Bahlis, Nizar
    Facon, Thierry
    Plesner, Torben
    Orlowski, Robert Z.
    Nahi, Hareth
    Hulin, Cyrille
    Quach, Hang
    Goldschmidt, Hartmut
    O'Dwyer, Michael
    Perrot, Aurore
    Venner, Christopher P.
    Weisel, Katja
    Raje, Noopur
    Tiab, Mourad
    Macro, Margaret
    Frenzel, Laurent
    Leleu, Xavier
    Pei, Huiling
    Krevvata, Maria
    Borgsten, Fredrik
    Usmani, Saad Z.
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 17 - 18
  • [50] Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma
    Kapoor, Prashant
    Gertz, Morie A.
    Laplant, Betsy
    Malave, Gabriella C.
    Wolfe, Eric
    Muchtar, Eli
    Siddiqui, Mustaqeem A.
    Gonsalves, Wilson I.
    Emanuel, Angie R.
    Kourelis, Taxiarchis
    Warsame, Rahma
    Dingli, David
    Buadi, Francis K.
    Hayman, Suzanne R.
    Leung, Nelson
    Hwa, Yi L.
    Hobbs, Miriam A.
    Fonder, Amie
    Dispenzieri, Angela
    Lacy, Martha Q.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    BLOOD, 2019, 134